NR Beat NMN by 2.3x: What the New 2026 NAD+ Trials Found

Two major 2026 human trials just dropped comparing NMN and NR — the two most popular NAD+ precursor supplements — and the results are surprising. In one study, researchers stopped the NMN arm early because NR was 2.3x more effective at raising blood NAD+. But a second trial found them essentially tied. So which one actually works? In this evidence-based deep dive, we break down the Bergen iScience trial, the Nestlé Research study, and what they really mean for anti-aging supplementation. We cover effective doses, safety considerations, the cancer warning, why most NMN brands on Amazon fail label testing, and whether IV NAD+ drips are worth the money. Plus: the bigger question nobody in the longevity space wants to ask — does raising NAD+ actually extend lifespan or just biomarkers? Topics covered: • NR vs NMN: head-to-head 2026 clinical results • Why NMN gets converted to NR in your body • Optimal dosing for NAD+ precursors • Safety, drug interactions, and who should avoid them • The supplement quality problem and how to buy smart If you found this useful, hit like, subscribe for more evidence-based longevity content, and tell us in the comments — team NR, team NMN, or team save-your-money?